De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
De-escalation from primarily natalizumab and fingolimod did not effectively ensure disease stability in this cohort. Younger age and inflammatory disease activity prior to de-escalation were risk factors for inflammatory disease activity post de-escalation, which can help guide future studies on de-escalation.
Authors
- Finn Thorup Sellebjerg (ORCID: https://orcid.org/0000-0002-1333-9623)
- Melinda Magyari (ORCID: https://orcid.org/0000-0002-0972-5222)
- Mie Reith Mahler (ORCID: https://orcid.org/0000-0003-0484-8220)
- Frederik Elberling (ORCID: https://orcid.org/0000-0002-4494-3671)
- Luigi Pontieri (ORCID: https://orcid.org/0000-0002-1506-3827)
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Multiple Sclerosis Center (DK)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/ene.70042
- Citations
- 7
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 10.30
Funders
- Deutschen Multiple Sklerose Gesellschaft